Your session is about to expire
← Back to Search
CAR T-cell Therapy
agenT-797 for Solid Tumors
Phase 1
Waitlist Available
Research Sponsored by MiNK Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 months
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new immune cell therapy called agenT-797 in patients whose solid tumors have come back or didn't respond to other treatments. The therapy uses special immune cells from a donor to help the patient's body fight the cancer.
Eligible Conditions
- Solid Tumors
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Cell Therapy
Number Of Participants With Treatment-emergent Adverse Events (TEAEs)
Number Of TEAEs By The Dose Of iNKT Cell Therapy
+1 moreSecondary study objectives
Duration Of Response (DOR)
Objective Response Rate (ORR)
Persistence Of agenT-797 In Peripheral Blood Samples
+1 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Part 2: agenT-797 in Combination with approved ICIsExperimental Treatment2 Interventions
Single prespecified dose of agenT-797 administered by IV infusion in combination with approved ICIs administered in accordance with manufacturer instructions and institutional guidelines as per standard of care
Group II: Part 1: Monotherapy with agenT-797Experimental Treatment1 Intervention
3+3 Dose escalation of agenT-797 will be administered as a single intravenous (IV) infusion.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
agenT-797
2022
Completed Phase 2
~70
Approved ICIs
2022
Completed Phase 1
~40
Find a Location
Who is running the clinical trial?
MiNK TherapeuticsLead Sponsor
2 Previous Clinical Trials
33 Total Patients Enrolled
Medical DirectorStudy DirectorMiNK Therapeutics
2,881 Previous Clinical Trials
8,088,168 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have another type of cancer at the same time.You have cancer that has spread to your brain or the covering of your brain and it is either not being treated or is currently being treated.
Research Study Groups:
This trial has the following groups:- Group 1: Part 1: Monotherapy with agenT-797
- Group 2: Part 2: agenT-797 in Combination with approved ICIs
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger